Your Cart


Levitra belongs to substances to treat erectile dysfunction. Levitra restores disordered erectile function and guarantees a normal response to sexual stimulation.

Composition and form of release

Pills covered by a film layer. It is of light orange to gray-orange color, round, biconvex tablets. It consists of components such as: vardenafil hydrochloride trihydrate, and etc.


The drug is taken orally, regardless of food intake. The initial recommended dose is 10 mg 25-60 minutes before sexual contact. It can also be taken 4-5 hours to 25 minutes before sexual activity. The maximum recommended frequency is 1 time/day. A sufficient level of sexual stimulation is required to achieve drug effectiveness.

Depending on the effectiveness and tolerability, the dose can be increased to 20 mg or reduced to 5 mg/day. The maximum daily dose is 20 mg.

Correction of the dosage regimen in elderly patients is not required.

In patients with mild hepatic insufficiency, correction of the dosage regimen is not required. In patients with moderate liver failure, the initial dose is 5 mg per day. Subsequently, depending on treatment effectiveness and tolerability, the dose can be increased to 10 mg and then to 20 mg.

In patients with mild and moderate renal impairment, dosage adjustment is not required.


Symptoms are back pain; treatment: symptomatic and supportive therapy (according to the clinical condition of the patient). The use of hemodialysis does not increase the clearance of vardenafil since it actively binds to blood plasma proteins. It is not excreted by the kidneys.


  • Hypersensitivity to the components of the drug;
  • The simultaneous use of nitrates or any NO donors (drugs emitting NO);
  • Under 18 years old;
  • The simultaneous use of HIV protease inhibitors indinavir and ritonavir, since they are potent inhibitors of CYP 3A4.

Side effects

  • Levitra is usually well-tolerated. Side effects are transient and slightly pronounced.
  • The most common (> 10% of cases): headache, flushing (facial flushing);
  • Frequent (1–10%): dizziness, dyspeptic symptoms, nausea, nasal congestion;
  • Infrequent (0.1–1%): photosensitivity of the skin, hypertension, back pain, lacrimation;
  • Single (0.01–0.1%): arterial hypotension, myalgia, priapism.

There are isolated cases of anterior ischemic neuropathy of the optic nerve were noted (as a result, vision decreases until its permanent loss), which is associated with the use of PDE-5 inhibitors, to which Levitra belongs. Most of the examined patients were exposed to vascular risk (severe stagnation of the optic nerve, over 50, diabetes, hypertension, cardiovascular disease, hyperlipidemia, and smoking). However, it has not been established whether these single cases of the disease directly related to the use of PDE-5 inhibitors in patients at vascular risk, or whether they should be attributed to other factors.